Navigation Links
Australian Business Mogul Bruce Mathieson Invests in iSonea
Date:8/31/2012

MELBOURNE, Australia and SEVERNA PARK, Md., Aug. 31, 2012 /PRNewswire/ -- Medical technology company iSonea Ltd (ASX: ISN; OTCQX: ISOAD) has raised $1.05 million via a private placement of shares to Investment Holdings Pty Ltd, an entity owned and controlled by prominent Australian businessman Bruce Mathieson.

(Logo:  http://photos.prnewswire.com/prnh/20120831/NE65948LOGO )

The share placement means Mathieson is now a cornerstone investor of the company, with a 15 percent ownership position. The placement covers the company's entire 15 percent issuance capacity and will be followed by an entitlement issue to all shareholders.

Announcing the placement, iSonea Chief Executive Officer Michael Thomas said the investment recognizes the pioneering nature of iSonea's asthma and acoustic respiratory monitoring (ARM™) technologies, as the company sets itself to lead in the global explosion of mobile health disease management.

Thomas continued: "iSonea is committed to developing innovative, non-invasive devices and mobile health applications to improve the management of chronic and costly respiratory disorders such as asthma and COPD.  After the successful launch of our AsthmaSense™ mobile smartphone app this summer, the company is now focused on integrating our existing proprietary ARM sensors and analytical software with the AsthmaSense mobile smartphone app to develop an app based wheeze monitor known as AirSonea™."

AirSonea will run on smartphone (iPhone and Android) platforms, enabling anyone, anywhere, at any time to conveniently monitor asthma events and take appropriate action to control the condition.

Mathieson has held a passionate interest in the IT revolution and the impact of mobile technology on the future of healthcare.  He was attracted to the iSonea business model, leadership team and the company's strong patent position in the respiratory device space.He commented: "iSonea is strongly positioned in the new area of digital health. The asthma monitoring device they are developing to operate with smart phones has enormous potential to help asthmatics worldwide and generate impressive recurring revenue."

"As the late Steve Jobs said in 2010, 'one of the biggest innovations of the 21st Century will be the intersection of biology and technology.  A new era is beginning, just like the digital one when I was my son's age.'  I believe iSonea's products are ahead of the curve and representative of the future of health management."

iSonea's Chairman Dr. Stewart Washer commented: "We welcome Bruce's vision and investment as an opportunity to pioneer the development of innovative digital health technologies which promise to change the way millions of asthma sufferers around the world can manage their conditions."

Mathieson is a respected member of the Australian business community, having built the Bruce Mathieson Group into a significant operation in the hospitality industry.  A joint venture with Woolworths led to the establishment of Australian Leisure and Hospitality Group Pty Ltd (The ALH Group).  Mathieson is a director and holds a 25 percent stake in ALH Group, having previously served as chief executive officer.  Successfully operating in the hospitality and leisure industry since 1974, Mathieson has management experience across several industries and is currently a non-executive director of Mayne Pharma Group Ltd. He is also owner/director of Payment Network International (PNI).  He has served as a director of the Carlton Football Club.

Patersons Securities acted as lead manager to the placement. The placement will be followed by an entitlement issue to all shareholders.  Details of the entitlement issue will follow. Mathieson also intends to participate in the entitlement issue.  Media Inquiries:Michael ThomasHelen Shik or Jen NetzbandChief Executive OfficerSchwartz MSL BostoniSonea Limited+1 781-684-077+1 410-777-525iSonea@schwartzmsl.com  mthomas@iSoneaMed.comwww.schwartzmsl.comWebsites: www.iSoneaMed.com, www.SoundAsthma.com

About iSonea Limited
iSonea Limited (ASX:ISN; OTCQX:ISOAY) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea's proprietary Acoustic Respiratory Monitoring™ (ARM) technology with its AsthmaSense™ mobile applications, iSonea is turning smart phones into medical devices--enabling anyone, anywhere, at any time to monitor breathing distress symptoms, in order to take action. iSonea's ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA and the European Union CE.

For more information, please visit www.iSoneaMed.com.

Forward Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on iSonea's current expectations, estimates and projections about the industry in which iSonea operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of iSonea, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. iSonea cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of iSonea only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. iSonea will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.


'/>"/>
SOURCE iSonea Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MGC Diagnostics Corporation Completes Sale of New Leaf Business Assets to Life Time - The Healthy Way of Life Company
2. The Thousand-Year Business Model for a Modern Biopharmaceutical Company
3. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
4. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
5. Human Circuit Recognized as an Industry Leader in Commercial Integrator Magazines Business Series as a Top 5 Healthcare Market Media Integrator for 2012
6. Organovo Reports Q2 2012 Financial Results, Provides Business Update
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
8. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
9. Alexza Reports 2012 Second Quarter Financial Results and Provides Business Update
10. AspenBio Pharma to Provide Shareholders with Business Update
11. Vesta Inc. Opens Frankfurt Office to Increase Service to Their Growing Medical Device Contracting Business Overseas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences Inc. ... to support the development of CRISPR-Cas3 antimicrobial therapeutics. Financing ... a leading Chinese Internet services provider, and joined by ... multiple infectious disease product programs targeting antibiotic resistant infections ... Founded by Dr. Rodolphe Barrangou and ...
(Date:7/5/2017)... 2017 Wolfmet 3D  printed tungsten collimator manufactured by M&I ... manufacturing combine to progress molecular radiotherapy imaging. In ... unable to accurately quantify the radiation absorbed by those patients ... success of this radiotherapy treatment has been available — that ... ...
(Date:7/5/2017)... , July 5, 2017 Pace Analytical, a company of over ... today that they have acquired ESC Lab Sciences, further solidifying their position as ... United States . ... Steve Vanderboom- President and CEO of Pace Analytical ... ESC Lab Sciences out of Mt Juliet, TN , enhances ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... Summers in Palm Springs sizzle, but ... — think homemade gourmet ice cream, sparkling pools, and mile-high fun. , At Arrive's ... mugs, journals, and other must-have knick knacks. Ice cream and sorbet flavors rotate, but ...
(Date:7/25/2017)... ... July 25, 2017 , ... Dr. Donna ... University recently co-authored and published an article in the medical science journal Physical ... Palsy. Both the article and the research that helped produce it, were written ...
(Date:7/25/2017)... Austin, TX (PRWEB) , ... July 25, 2017 , ... ... medical emergencies in the Austin, TX area 24 Hours a day. , The ... in Austin, TX. , “We’ve been open four months now and things are ...
(Date:7/24/2017)... ... July 24, 2017 , ... Cosmetic Town, an online plastic surgery ... surgeries they perform on a daily basis. , The new video series will ... specialize in at their practices. , When asked about the new video series, ...
(Date:7/24/2017)... ... July 24, 2017 , ... The International Essential Tremor Foundation (IETF) will ... essential tremor (ET). The seminar will take place on Saturday, Aug. 26 at the ... The program will run from 9 a.m. to 12 p.m., with check-in beginning at ...
Breaking Medicine News(10 mins):